Nevakar, Inc.

Nevakar Injectables Inc. received FDA approval for Cyclophosphamide Injection, 200mg/mL vials, designed for cancer combination therapy. Available in 500 mg / 2.5 mL and 1 gram / 5 mL vials, it aims to reduce waste, simplify preparation, and minimize dosing errors. This marks Nevakar's third NDA approval in a year, showcasing its innovation and commitment to healthcare value.